| Submission to first decision
(The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor) Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date. |
3 weeks |
|---|---|
| Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) | 6 weeks |
| Submission to final decision (The average time from manuscript submission to the final editorial decision) | 16 weeks |
| Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) | 24 weeks |
ACTA Pharmaceutica Sciencia
2024 , Vol 62 , Num 2
Efficacy of statin therapy on achieving target goal of LDL among Iraqi patients
1 Kut University College, School of Pharmacy, Department of Clinical Pharmacy, Alkut, Wasit, Iraq2 Al-Yarmouk University College, School of Pharmacy, Department of Clinical Pharmacy Baqubah/Diyala, Iraq
DOI : 10.23893/1307-2080.APS6218 Viewed : 5159 - Downloaded : 1746 Dietary and statin treatment planning are central to the management of dyslipidemia. The treatment"s efficacy is determined by how well it achieves the level of low-density lipoprotein (LDL)- target goal established by European guidelines for that reason the target (LDL) in patients receiving different types and doses of statin therapy were evaluated in this prospective, cross-sectional study was conducted on patients recruited from Al Karama Teaching Hospital, Kut, Iraq to assess the levels of serum LDL in addition to data collected directly from the patients included demographic characteristics, BMI, and types, doses, and duration of statins used which showed that target goal (optimal) was achieved in 82.4% in patients taking statin. The LDL-target goal was achieved in 85.4% of patients taking statin with moderate risk, in 82.6% with high risk, and 80.6 % with very high risk which indicate that the targeted LDL levels were achieved in good proportion in patients with high and moderate risk of dyslipidemia with a less extent proportion in patients with very high-risk of dyslipidemia. It was also demonstrated that the LDL target levels were achieved more efficiently with a higher dose of statins. Keywords : cardiovascular diseases, dyslipidemia, statin target goal